New data show systemic delivery of antimiR-23b developed on ARTHEx BOOST-ONplatform reaches the brain, corrects disease biology, and improves behavior-highlighting potential to address CNS manifestations of DM1
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/arthex-biotech-publishes-first-demonstration-of-improvement-in-a-dm1-related-behavioral-alteration-in-a-preclinical-model-of-myotonic-dystrophy-type-1-dm1-302833041.html

© 2026 PR Newswire
